Stable disease lasting for more than 2.5 months (range, 2.6 to 5.5 months) was observed in six patients. These results demonstrate that pertuzumab is well tolerated, has a pharmacokinetic profile ...

SAN DIEGO, CA, USA I June 03, 2025 I Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage biotechnology company developing next-generation oncology ...

“Vitamin A dimerization has been implicated in the formation of lipofuscin and [retinal pigment epithelium] and photoreceptor degeneration,” Melamud said. “Therefore, it is our hypothesis ...

Merck Sharp & Dohme LLC has identified targeted activator of cell kill (TACK) compounds acting as Gag polyprotein (HIV-1)/protein Pol dimerization inducers reported to be useful for the treatment of ...